Bio­gen los­es CMO, neu­ro­mus­cu­lar leader; John Hood adds pres­i­dent, CFO at En­deav­or Bio­Med­i­cines

→ Bio­gen chief med­ical of­fi­cer Ma­ha Rad­hakr­ish­nan is out af­ter four years “as of March 1,” a spokesper­son tells Peer Re­view. Bio­gen didn’t draw up a press re­lease for her de­par­ture, but a board ap­point­ment at NYSE new­com­er Al­to Neu­ro­science was the first in­di­ca­tion that Rad­hakr­ish­nan de­cid­ed to leave. In her sec­ond time around at the big biotech, the Alzheimer’s drug Aduhelm flamed out, while the Ei­sai-part­nered fol­low-up Leqem­bi earned a full FDA ap­proval as Eli Lil­ly waits on the side­lines with do­nanemab. From 2013-16, Rad­hakr­ish­nan was Bio­gen’s VP, US med­ical and VP, Eu­rope and Cana­da med­ical be­fore her tenure at Biover­a­tiv and Sanofi. “Ma­ha made many im­por­tant con­tri­bu­tions to Bio­gen and the pa­tients we serve — most no­tably es­tab­lish­ing our frame­work for ear­ly pa­tient ac­cess, en­abling many pa­tients to ben­e­fit from im­por­tant and po­ten­tial­ly life­sav­ing new ther­a­pies glob­al­ly,” a Bio­gen spokesper­son said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER